The in-vivo model for AD demonstrated that besides the inhibition of T-cell activation and reduction in inflammatory gene expression, PPARγ agonists also increase levels of neuroprotective and anti-inflammatory molecules, including heat shock protein 70 (HSP70) and inhibitory proteins NF-kappa-B inhibitor alpha (IkBα) and NF-kappa-B inhibitor beta (IkBβ) (Feinstein, 2004). This evidence concerns the gene PPARG and Alzheimer disease.